Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for GSK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 410.58M
March 31, 2026 428.47M
December 31, 2025 327.56M
September 30, 2025 448.47M
June 30, 2025 729.79M
March 31, 2025 295.94M
December 31, 2024 -0.4416M
September 30, 2024 -1.353M
June 30, 2024 -1.188M
March 31, 2024 -22.82M
December 31, 2023 -1.085M
September 30, 2023 -0.1527M
June 30, 2023 -3.843M
March 31, 2023 -7.290M
December 31, 2022 0.9079M
September 30, 2022 -9.343M
June 30, 2022 -8.684M
March 31, 2022 -13.41M
December 31, 2021 -1.042M
September 30, 2021 -1.357M
June 30, 2021 -5.76M
March 31, 2021 -20.68M
December 31, 2020 -1.974M
September 30, 2020 -2.470M
June 30, 2020 -3.331M
Date Value
March 31, 2020 -29.39M
December 31, 2019 -11.92M
September 30, 2019 -9.505M
June 30, 2019 -7.868M
March 31, 2019 -35.16M
December 31, 2018 -57.56M
September 30, 2018 -9.829M
June 30, 2018 -16.64M
March 31, 2018 -15.31M
December 31, 2017 -3.797M
September 30, 2017 -4.787M
June 30, 2017 -15.79M
March 31, 2017 35.93M
December 31, 2016 -13.27M
September 30, 2016 -50.86M
June 30, 2016 -16.96M
March 31, 2016 60.91M
December 31, 2015 -45.86M
September 30, 2015 16.99M
June 30, 2015 15.88M
March 31, 2015 52.87M
December 31, 2014 -66.03M
September 30, 2014 10.36M
June 30, 2014 295.47M
March 31, 2014 34.91M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 600.99M
Eli Lilly & Co. 1.601B
Merck & Co., Inc. 714.00M
Pfizer Inc. 0.00
Sanofi --